Introduction/Beyond SSRIs

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

This supplement (1) reviews new developments in our understanding of the mechanisms of action, therapeutic efficacy, and satety of antidepressants (especially bupropion), (2) provides an update on antidepressant interactions, (3) presentsnew data on bupropion for smoking cessation and attention-deficit/hyperactivity disorder(ADHD), and (4) evaluates proposed medication management plans (e.g., algorithms)for the treatment of depressed phase bipolar disorder.